“Potential safety concern” halts clinical trial of Eli Lilly antibody treatment

Edited by Ed Newman
2020-10-14 11:55:07

Pinterest
Telegram
Linkedin
WhatsApp

Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug. (Photo: Internet)

Indianapolis, October 14 (RHC)-- Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug over an unspecified “potential safety concern.”

President Donald Trump touted a similar drug produced by Regeneron as a “cure” for COVID-19 after he received a dose while hospitalized at Walter Reed Medical Center earlier this month. 

Both Eli Lilly and Regeneron have applied for emergency use authorizations of their antibody therapies.
 



Commentaries


MAKE A COMMENT
All fields required
NOT TO BE PUBLISHED
captcha challenge
up